Please use this identifier to cite or link to this item: http://localhost:80/xmlui/handle/123456789/13199
Title: 3-chloromethylene-6-fluorothiochroman-4-one, A novel DNA Topoisomerase poison
Authors: Wang, Yitian
Chen, Juntao
Shen, Rui
Yang, Chunliu
Ma, Zhengyue
Liu, Yuxin
Keywords: 3-chloromethylene-6-fluorothiochroman-4-one (CMFT)
cis-and trans-isomers
anti-tumor activity
topoisomerase
Issue Date: 16-Nov-2016
Publisher: Karachi: Faculty of Pharmacy & Pharmaceutical Sciecnes, University of Karachi
Abstract: : 3-Chloromethylene-6-fluorothiochroman-4-one (CMFT) is a novel thiochromanones derivative that has better anti-tumor activity. In this paper, we will compare the antitumor activity of the cis-trans isomers, and explore their inhibiting effects on human topoisomerase I and topoisomerase II in cell free reaction system. The MTT method was used to study inhibition rates; the AO/EB double staining and TUNEL assay was used to assess proportion of apoptotic cells. The inhibition of CMFT to Topo I and II could be identified by adding CMFT solutions to Topo-DNA reaction mixtures and observing the relative quantities of relaxed strands and supercoils in electrophoresis assay. Results showed that CMFT had dramatic anti-tumor activities at low concentrations and the activity of CMFT trans-isomer is more significant. Use of AO/EB double staining and TUNEL indicated that CMFT induces apoptosis. DNA relaxation assays and DNA cleavage and relegation assays were performed and showed a higher potential to interact with topoisomerase I (Topo I) and topoisomerase II (Topo II) and it was verified that CMFT is a Topo poison which could be one of the mechanisms that induce cell apoptosis. Our results provide preliminary data for further investigation for the mechanism of CMFT of the apoptotic mechanism.
URI: http://142.54.178.187:9060/xmlui/handle/123456789/13199
ISSN: 1011-601X
Appears in Collections:Issue 6

Files in This Item:
File Description SizeFormat 
18-SUP-574.htm147 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.